Possibia

745589

Last Update Posted: 2020-06-18

Recruiting has ended

All Genders

accepted

25 Years-80 Years

60 Estimated Participants

No Expanded Access

Interventional Study

Does not accept healthy volunteers

Sevelamer Hydrochloride in Peritoneal Dialysis Patients

To test the hypothesis that second-line fixed low-dose sevelamer hydrochloride therapy is as effective as first-line high-dose sevelamer hydrochloride therapy in limiting the progression of cardiovascular calcification.

Cardiovascular disease accounts for nearly 50% of the mortality and is the most frequent cause of hospitalization in ESRD patients. Hyperphosphatemia is increasingly recognized to be an important predictor of mortality and cardiovascular death in ESRD patients and is largely attributed to the increased prevalence of vascular calcification.

Eligibility

Relevant conditions:

Endstage Renal Disease

If you aren't sure if you meet the criteria above speak to your healthcare professional. Criteria may be updated but not reflected here, do not hesitate to contact the trial if you think are close to fitting criteria.

locations

Contact Information

Overall Contact

No valid contacts available

Data sourced from ClinicalTrials.gov